{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:11Z","timestamp":1787584571800,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005362","name":"Universit\u00e0 degli Studi di Bari","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anndiagpath.2026.152622","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:41:22Z","timestamp":1770136882000},"page":"152622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["LEF1 and IL13RA2 in testicular sex cord\u2013stromal tumors: LEF1 as a potential diagnostic marker for Sertoli cell tumors"],"prefix":"10.1016","volume":"82","author":[{"given":"Mario Della","family":"Mura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Sorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Musci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Nenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D'Amuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Lavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anndiagpath.2026.152622_bb0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PAP.0000000000000423","article-title":"Contemporary updates on sex cord-stromal tumors of the testis","volume":"31","author":"Acosta","year":"2024","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2026.152622_bb0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/his.15482","volume":"87","author":"Acosta","year":"2025","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0015","first-page":"1","article-title":"Sex cord-stromal tumors of the testis\u2014a rare group of benign and malignant gonadal neoplasms: a literature review","volume":"20","author":"Zieli\u0144ska","year":"2024","journal-title":"Oncol Clin Pract"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0020","unstructured":"WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. 5th ed. Volume 8. Lyon: International Agency for Research on Cancer; 2022. Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/36."},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0025","doi-asserted-by":"crossref","unstructured":"Rizzo NM, Sholl LM, Idrees MT, et al. Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. Mod Pathol 2021;34(11):1935\u20131946. doi:https:\/\/doi.org\/10.1038\/s41379-021-00845-3.","DOI":"10.1038\/s41379-021-00845-3"},{"issue":"8","key":"10.1016\/j.anndiagpath.2026.152622_bb0030","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1210\/jc.2006-0183","article-title":"Adult Leydig cell tumors of the testis caused by germline fumarate hydratase mutations","volume":"91","author":"Carvajal-Carmona","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.anndiagpath.2026.152622_bb0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.juro.2006.07.005","article-title":"Long-term follow-up and clinical characteristics of testicular Leydig cell tumor: experience with 24 cases","volume":"176","author":"Carmignani","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2026.152622_bb0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.juro.2016.03.143","article-title":"Patterns of care and survival outcomes for malignant sex cord stromal testicular cancer: results from the National Cancer Data Base","volume":"196","author":"Banerji","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2026.152622_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/his.14225","article-title":"The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification","volume":"78","author":"Colecchia","year":"2021","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.anndiagpath.2026.152622_bb0050","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clgc.2016.08.001","article-title":"Characteristics of patients with Sertoli and Leydig cell testis neoplasms from a national population-based registry","volume":"15","author":"Osbun","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.anndiagpath.2026.152622_bb0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5858\/2007-131-311-AILALC","article-title":"An in-depth look at Leydig cell tumor of the testis","volume":"131","author":"Al-Agha","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/PAS.0b013e31829cdbc6","article-title":"Frequent mutation and nuclear localization of \u03b2-catenin in Sertoli cell tumors of the testis","volume":"38","author":"Perrone","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2026.152622_bb0065","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/PAS.0000000000001527","article-title":"A morphologic and immunohistochemical comparison of nuclear \u03b2-catenin-expressing testicular Sertoli cell tumors and pancreatic solid pseudopapillary neoplasms supporting their continued separate classification","volume":"44","author":"Kao","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jcp-2024-209695","article-title":"Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for \u03b2-catenin (CTNNB1) mutations","volume":"79","author":"Hewer","year":"2025","journal-title":"J Clin Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2026.152622_bb0075","article-title":"Interleukin 13 receptor alpha 2 (IL13R\u03b12): expression, signaling pathways, and therapeutic applications in cancer","volume":"1877","author":"Ja\u00e9n","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"10.1016\/j.anndiagpath.2026.152622_bb0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00000478-199806000-00008","article-title":"Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases","volume":"22","author":"Young","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2026.152622_bb0085","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1101\/gad.1424006","article-title":"Wnt signaling: is the party in the nucleus?","volume":"20","author":"Willert","year":"2006","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12957-025-03675-8","article-title":"Diagnostic utility of LEF1 and \u03b2-catenin in WNT pathway tumors with CTNNB1 mutation","volume":"23","author":"Li","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2026.152622_bb0095","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrm2654","article-title":"Beta-catenin hits chromatin: regulation of Wnt target gene activation","volume":"10","author":"Mosimann","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5382","key":"10.1016\/j.anndiagpath.2026.152622_bb0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.281.5382.1509","article-title":"Identification of c-MYC as a target of the APC pathway","volume":"281","author":"He","year":"1998","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.anndiagpath.2026.152622_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/path.1692","article-title":"Wnt signalling and the mechanistic basis of tumour development","volume":"205","author":"Ilyas","year":"2005","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2026.152622_bb0110","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","article-title":"Nuclear \u03b2-catenin localization and mutation of the CTNNB1 gene: a context-dependent association","volume":"31","author":"Kim","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0115","doi-asserted-by":"crossref","unstructured":"Hagen T, Sethi JK, Foxwell N, et al. Signalling activity of beta-catenin targeted to different subcellular compartments. Biochem J 2004;379(3):471\u2013477. doi:https:\/\/doi.org\/10.1042\/BJ20031749.","DOI":"10.1042\/bj20031749"},{"issue":"5","key":"10.1016\/j.anndiagpath.2026.152622_bb0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/pin.13096","article-title":"A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used anti-beta-catenin antibodies","volume":"71","author":"Yamada","year":"2021","journal-title":"Pathol Int"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/cup.13806","article-title":"Nuclear \u03b2-catenin immunoexpression in scars","volume":"48","author":"Goto","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.anndiagpath.2026.152622_bb0130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/modpathol.3880409","article-title":"Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma","volume":"14","author":"Sugimachi","year":"2001","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2026.152622_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/gutjnl-2020-322983","article-title":"Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis","volume":"71","author":"Goeppert","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0140","doi-asserted-by":"crossref","unstructured":"Nei H, Saito T, Yamasaki H, et al. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999;25(3):207\u2013218.","DOI":"10.1002\/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.0.CO;2-4"},{"issue":"6","key":"10.1016\/j.anndiagpath.2026.152622_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0344-0338(98)80129-5","article-title":"Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front","volume":"194","author":"Brabletz","year":"1998","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-019-0444-1","article-title":"Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation","volume":"17","author":"Hao","year":"2019","journal-title":"Cell Commun Signal"},{"issue":"38","key":"10.1016\/j.anndiagpath.2026.152622_bb0155","doi-asserted-by":"crossref","first-page":"33398","DOI":"10.1074\/jbc.M107977200","article-title":"Wnt-3A\/beta-catenin signaling induces transcription from the LEF-1 promoter","volume":"277","author":"Filali","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.anndiagpath.2026.152622_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.0105-2896.2004.00210.x","article-title":"Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease","volume":"202","author":"Mentink-Kane","year":"2004","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.anndiagpath.2026.152622_bb0165","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","article-title":"Molecular basis for shared cytokine recognition revealed in the structure of an unusually high-affinity complex between IL-13 and IL-13Ralpha2","volume":"18","author":"Lupardus","year":"2010","journal-title":"Structure"},{"issue":"4","key":"10.1016\/j.anndiagpath.2026.152622_bb0170","first-page":"1168","article-title":"Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas","volume":"60","author":"Joshi","year":"2000","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2026.152622_bb0175","first-page":"985","article-title":"Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas","volume":"5","author":"Debinski","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.anndiagpath.2026.152622_bb0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-017-2680-9","article-title":"Analysis of The Cancer Genome Atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor \u03b11 and \u03b12 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme","volume":"136","author":"Han","year":"2018","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2026.152622_bb0185","article-title":"IL-13R\u03b12 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma","volume":"16","author":"Kumar","year":"2021","journal-title":"PloS One"},{"issue":"17","key":"10.1016\/j.anndiagpath.2026.152622_bb0190","first-page":"6381","article-title":"Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker","volume":"9","author":"Kawakami","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.anndiagpath.2026.152622_bb0195","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.22134","article-title":"Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy","volume":"107","author":"Kioi","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.anndiagpath.2026.152622_bb0200","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.1158\/0008-5472.CAN-09-2100","article-title":"A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis","volume":"69","author":"Fujisawa","year":"2009","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.anndiagpath.2026.152622_bb0205","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1158\/1078-0432.CCR-21-0361","article-title":"IL13R\u03b12 promotes proliferation and outgrowth of breast cancer brain metastases","volume":"27","author":"M\u00e1rquez-Ortiz","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0210","doi-asserted-by":"crossref","unstructured":"Kang MA, Lee J, Lee CM, et al. IL13R\u03b12 is involved in the progress of renal cell carcinoma through the JAK2\/FOXO3 pathway. J Pers Med 2021;11(4):284. doi:https:\/\/doi.org\/10.3390\/jpm11040284.","DOI":"10.3390\/jpm11040284"},{"issue":"17","key":"10.1016\/j.anndiagpath.2026.152622_bb0215","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.anndiagpath.2026.152622_bb0220","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/0008-5472.CAN-11-4090","article-title":"High expression of IL-13 receptor \u03b12 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis","volume":"72","author":"Barderas","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.anndiagpath.2026.152622_bb0225","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1158\/0008-5472.CAN-14-3650","article-title":"IL13 receptor \u03b12 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis","volume":"75","author":"Bartolom\u00e9","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878365","article-title":"Recent advances in IL-13R\u03b12-directed cancer immunotherapy","volume":"13","author":"Knudson","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2026.152622_bb0235","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41416-018-0259-7","article-title":"An IL13R\u03b12 peptide exhibits therapeutic activity against metastatic colorectal cancer","volume":"119","author":"Bartolom\u00e9","year":"2018","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.anndiagpath.2026.152622_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071731","article-title":"Inhibition of liver metastasis in colorectal cancer by targeting IL-13\/IL13R\u03b12 binding site with specific monoclonal antibodies","volume":"13","author":"Ja\u00e9n","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anndiagpath.2026.152622_bb0245","doi-asserted-by":"crossref","unstructured":"Fujisawa T, Joshi BH, Takahashi S, et al. IL-13R\u03b12 is a biomarker of diagnosis and therapeutic response in human pancreatic cancer. Diagnostics 2021;11(7):1140. doi:https:\/\/doi.org\/10.3390\/diagnostics11071140.","DOI":"10.3390\/diagnostics11071140"},{"issue":"25","key":"10.1016\/j.anndiagpath.2026.152622_bb0250","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:53:05Z","timestamp":1773233585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913426000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S1092913426000183"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152622","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LEF1 and IL13RA2 in testicular sex cord\u2013stromal tumors: LEF1 as a potential diagnostic marker for Sertoli cell tumors","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152622"}}